Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

被引：75
作者：
Cai, Yi [1 ]
Dodhia, Sonam [1 ]
Su, Gloria H. [1 ,2 ,3 ]
机构：
[1] Columbia Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10027 USA
[2] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA
[3] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA
来源：
ONCOTARGET | 2017年 / 8卷 / 13期
关键词：
PI3K signaling; head and neck squamous cell carcinoma; PIK3CA mutation; PI3K inhibitor; personalized medicine;
D O I：
10.18632/oncotarget.14729
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.
引用
收藏
页码：22203 / 22217
页数：15
相关论文
共 108 条
[1]   Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].
Ali, Khaled ;
Soond, Dalya R. ;
Pineiro, Roberto ;
Hagemann, Thorsten ;
Pearce, Wayne ;
Lim, Ee Lyn ;
Bouabe, Hicham ;
Scudamore, Cheryl L. ;
Hancox, Timothy ;
Maecker, Heather ;
Friedman, Lori ;
Turner, Martin ;
Okkenhaug, Klaus ;
Vanhaesebroeck, Bart .
NATURE, 2014, 510 (7505) :407-+
[2]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[3]   Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 [J].
Amornphimoltham, P ;
Sriuranpong, V ;
Patel, V ;
Benavides, F ;
Conti, CJ ;
Sauk, J ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4029-4037
[4]   The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas [J].
Anderson, Ryan T. ;
Keysar, Stephen B. ;
Bowles, Daniel W. ;
Glogowska, Magdalena J. ;
Astling, David P. ;
Morton, J. Jason ;
Le, Phuong ;
Umpierrez, Adrian ;
Eagles-Soukup, Justin ;
Gan, Gregory N. ;
Vogler, Brian W. ;
Sehrt, Daniel ;
Takimoto, Sarah M. ;
Aisner, Dara L. ;
Wilhelm, Francois ;
Frederick, Barbara A. ;
Varella-Garcia, Marileila ;
Tan, Aik-Choon ;
Jimeno, Antonio .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) :1994-2005
[5]  
[Anonymous], HISTOPATHOLOGY
[6]   A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer [J].
Argiris, Athanassios ;
Cohen, Ezra ;
Karrison, Theodore ;
Esparaz, Benjamin ;
Mauer, Ann ;
Ansari, Rafat ;
Wong, Stuart ;
Lu, Yi ;
Pins, Michael ;
Dancey, Janet ;
Vokes, Everett .
CANCER BIOLOGY & THERAPY, 2006, 5 (07) :766-770
[7]   A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma [J].
Bauman, Julie E. ;
Arias-Pulido, Hugo ;
Lee, Sang-Joon ;
Fekrazad, M. Houman ;
Ozawa, Hiroyuki ;
Fertig, Elana ;
Howard, Jason ;
Bishop, Justin ;
Wang, Hao ;
Olson, Garth T. ;
Spafford, Michael J. ;
Jones, Dennie V. ;
Chung, Christine H. .
ORAL ONCOLOGY, 2013, 49 (05) :461-467
[8]  
Bozec A, 2016, HEAD NECK
[9]   The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies [J].
Broek, R. Vander ;
Mohan, S. ;
Eytan, D. F. ;
Chen, Z. ;
Van Waes, C. .
ORAL DISEASES, 2015, 21 (07) :815-825
[10]   Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma [J].
Bruckman, Karl C. ;
Schoenleben, Frank ;
Qiu, Wanglong ;
Woo, Victoria L. ;
Su, Gloria H. .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2010, 110 (05) :632-637
12345678910